Animate Biosciences, a San Francisco-based biotechnology company, has unveiled its innovative AnimateIQ™ platform designed to develop first-of-its-kind peptide therapeutics for treating inflammatory and fibrotic diseases—conditions affecting nearly every organ system and contributing to nearly half of global deaths. These diseases, including pulmonary fibrosis, skin scarring, and cardiac fibrosis, have long lacked safe and effective treatments. Animate Biosciences aims to change that by combining multi-omics data from highly regenerative species—such as salamanders and axolotls—with generative artificial intelligence and rapid peptide synthesis. The company’s proprietary platform analyzes biological signals from species capable of regenerating tissues without scarring, translating those natural mechanisms into precisely engineered peptides. These peptides are designed to modulate inflammation and fibrosis at the cellular level, with the ultimate goal of not just slowing but preventing or even reversing disease progression. Animate has initiated lead programs in pulmonary and dermatological diseases and is collaborating on research in cardiac fibrosis, building a scalable pipeline targeting both rare and common conditions. The company is led by a seasoned leadership team with deep expertise in biotech innovation and drug development. Peter Licari, CEO, brings experience from major pharmaceutical successes including Humira (BASF) and Vaqta (Merck). Jessica Whited, PhD, Chief Science Officer and Associate Professor at Harvard University, is a leading authority in regenerative biology and stem cell science, with a PhD from MIT and postdoctoral training at Harvard Medical School. Jonathan Wolfson, Executive Chair, is a serial entrepreneur and founder of Solazyme, Algenist, and Brainiac Foods, with a proven track record in scaling science-driven enterprises. The core team includes Domarin Khago (Protein Chemistry Lead), Chi Hai Ly (Biology Lead), and Benjamin Orr (AI & Computational Biology Lead), who are driving the integration of AI and experimental biology. Animate is further supported by a distinguished advisory board across key medical fields. Experts include Lonny Yarmus, DO, a pulmonology leader at Johns Hopkins; Charles A. Powell, MD, MBA, a top figure in pulmonary and critical care medicine at Mount Sinai; Howard Maibach, MD, a renowned dermatologist at UCSF specializing in skin disorders and pharmacology; Dipanjan Chowdhury, PhD, a Harvard radiation oncologist studying DNA repair; and Adam Schaffner, MD, a board-certified plastic surgeon and expert in tissue regeneration. Animate Biosciences was founded on the belief that the body’s innate regenerative potential can be harnessed to treat chronic diseases. By learning from nature’s most effective regenerators, the company aims to transform the treatment of inflammation and fibrosis across organ systems, making advanced therapies more accessible. The platform’s use of generative AI allows for rapid, data-driven design of peptides that are not only effective but also well-tolerated, reducing the risk of side effects. The company’s approach represents a new frontier in drug discovery, merging regenerative biology, AI, and precision medicine. With a mission to make life-altering and life-ending fibrotic diseases a thing of the past, Animate Biosciences is positioning itself at the forefront of next-generation therapeutics. For more information, visit animate.bio.